GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients benefit from treatment with GLP-1RAs. Initial results were presented at this year’s congress of the European Academy of Dermatology and Venereology (EADV).
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Ulcerative colitis
Rgs14 protein can worsen the severity
- Mastocytosis
Innovative pathogenesis-based therapeutic approaches in the pipeline
- Psychooncology
Communication as the key to therapy adherence
- Participation of the patient
Adherence in psychiatry
- From symptom to diagnosis
Renal cell carcinoma
- Lipid management: ESC/EAS guideline update 2025
New recommendations on CVD risk classification, lipid lowering in statin intolerance and hoFH
- Chronically active MS lesions
New paradigm in the diagnosis and treatment of multiple sclerosis
- AI in neurology